Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
30 août 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
25 août 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
03 août 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics,...
Aclaris Therapeutics Expands Leadership Team
01 août 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company...
Aclaris Therapeutics Expands Leadership Team
27 juin 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
Appoints Gail Cawkwell, MD, PhD, as Chief Medical Officer WAYNE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company...
Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
01 juin 2022 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
16 mai 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
10 mai 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
Clinical Sites Activated for Phase 2b Trial of ATI-1777April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:...
Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
03 mai 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
24 févr. 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...